PARG

IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

Retrieved on: 
Tuesday, March 12, 2024
MSD, PARG, Apoptosis, Prostate cancer, Endometrial cancer, Colorectal cancer, RECIST, Patient, MSI, Merck & Co., Pembrolizumab, Medicine, MSS, Breast cancer, HRD, Therapy, ADP, PD-1, Pharmaceutical industry

"We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.

Key Points: 
  • "We are excited to enter this collaboration as it allows study within and beyond the homologous recombination deficient (HRD) setting in endometrial cancer," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences.
  • "We are very pleased to collaborate with Merck on this trial evaluating IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer.
  • Under the clinical trial collaboration and supply agreement, Merck will provide KEYTRUDA to IDEAYA, which will be the sponsor of the Phase 1 clinical combination trial.
  • The mechanistic rationale and preclinical data to support the IDE161 and PD-1 clinical combination will be provided as part of a future R&D update.

Blacksmith Medicines Announces Upcoming Presentation at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
SAN, PARG, San Diego Convention Center, Blacksmith, FEN1, USP1, AACR, ATR, PARP, Pharmaceutical industry

SAN DIEGO, March 6, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced the company will present data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.

Key Points: 
  • SAN DIEGO, March 6, 2024 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced the company will present data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA.
  • Details of the poster presentation are as follows:
    Title: "Small molecule inhibitor of FEN1 nuclease utilizing a novel metal binding pharmacophore synergizes with inhibitors of USP1, PARP, PARG and ATR"

858 Therapeutics Expands Leadership Team to Support Transition to the Clinic

Retrieved on: 
Wednesday, December 20, 2023
Other Health, Hospitals, Health, Clinical Trials, Oncology, Texas Lutheran University, Eli Lilly, DNA, Therapy, PARG, PARP, DNA repair, Death, Doctor of Philosophy, Patient, AbbVie, Pharmaceutical industry

858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • 858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.
  • The addition of Dr. Bell-McGuinn strengthens the 858 Therapeutics leadership team as the company prepares to initiate clinical trials in 2024.
  • Dr. Bell-McGuinn brings extensive clinical development experience to 858 Therapeutics.
  • “We’re excited to welcome Kathy to the 858 Therapeutics leadership team.

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, December 6, 2023
Renal cell carcinoma, Assistant, Bristol Myers Squibb, Therapy, Mechanical engineering, IND, Physician, Mount Sinai School, Biotechnology, Breast cancer, Patient, Medical Affairs Bureau, Myeloid-derived suppressor cell, Princeton University, Messenger, BSE, PARG, Myeloid tissue, Cancer, BMS, Immunotherapy, Mechanical, Pharmaceutical industry, Surgeon, Medicine, Vivo

CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.
  • as Chief Medical Officer.
  • "We are very pleased that Matt has joined Myeloid as our Chief Medical Officer.
  • Dr. Maurer received a BSE in Mechanical Engineering from Princeton University and earned his medical degree from the Mount Sinai School of Medicine.

IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference

Retrieved on: 
Wednesday, November 1, 2023
Phase II, PARG, Therapy, Conference, Biotechnology, Medicine, GSK, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Nov. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Jefferies London Healthcare Conference and its plans to host an Investor R&D Day in December 2023.
  • In addition, IDEAYA will highlight its next generation initiatives in MTAP-deletion, including a wholly-owned program where a development candidate nomination is targeted in 2024, further advancing IDEAYA's multi-pronged strategy.
  • A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events .
  • A replay of available webcasts will be accessible for 30 days following the live event.

IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors

Retrieved on: 
Wednesday, April 19, 2023
GSK, Amgen, DNA, University of Manchester, AACR, University, Therapy, DDR, NCT, ADP, HRD, Neoplasm, Section 13, Cancer, Cancer Research UK, Breast, PARG, Associate, MD Anderson Cancer Center, Patient, Medicine, Abid, Poster, Ovarian cancer, PARP, Biology, Safety, Breast cancer, Medical imaging, Pharmaceutical industry, Vaccine, Genetics

SOUTH SAN FRANCISCO, Calif., April 19, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced achievement of First-Patient-In in the Phase 1 clinical trial evaluating IDE161 (NCT 05787587) and release of a poster presentation profiling IDE161 at AACR 2023.  IDE161 is a potent, selective, small-molecule inhibitor of PARG, a novel and mechanistically-differentiated target in the same clinically validated pathway as poly (ADP-ribose) polymerase (PARP).

Key Points: 
  • IDE161 is a potent, selective, small-molecule inhibitor of PARG, a novel and mechanistically-differentiated target in the same clinically validated pathway as poly (ADP-ribose) polymerase (PARP).
  • "We are excited to clinically investigate IDE161 as a potential first-in-class synthetic lethality treatment for cancer patients with homologous recombination deficiencies (HRD).
  • IDEAYA's Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties and preliminary efficacy of IDE161 as monotherapy in patients having tumors with homologous recombination deficiency (HRD).
  • The clinical protocol includes dose escalation in solid tumors with HRD.

Power Americas Resource to Attend and Showcase Twin Infra at Autodesk Conference

Retrieved on: 
Thursday, March 2, 2023
PDM, Conference, PARG, Autodesk, OTC, Digital twin, CFO, Video game, Alexander Croskery

MIRAMAR, FL, March 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Power Americas Resource Group Ltd. (OTC: PARG) (the “Company” or “PARG”), a publicly traded, fully reporting emerging growth company commercializing its Digital Twin technology “Twin Infra” for the international construction industry, is pleased to announce that the Company will attend the Autodesk One Team conference (the “Conference”) in Nashville, TN from March 6-9, 2023 where the Company will be showcasing a preview of its Twin Infra technology.

Key Points: 
  • MIRAMAR, FL, March 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Power Americas Resource Group Ltd. (OTC: PARG) (the “Company” or “PARG”), a publicly traded, fully reporting emerging growth company commercializing its Digital Twin technology “Twin Infra” for the international construction industry, is pleased to announce that the Company will attend the Autodesk One Team conference (the “Conference”) in Nashville, TN from March 6-9, 2023 where the Company will be showcasing a preview of its Twin Infra technology.
  • The Company’s Chairman & CFO, Ramasamy Balasubramanian, as well as the Company’s CTO, Kirubakaran Candasamy, will be attending the Conference on behalf of the Company.
  • The Company anticipates showcasing this same “sneak peek” into its technology during the Conference.
  • “We are elated to have what will in essence be a soft grand opening at Autodesk to an absolutely ideal demographic of large-scale customers and industry influencers who could hasten early adoption of our technology,” stated Mark Croskery, Chief Executive Officer, Power Americas Resource Group.

Power Americas Resource Group Ltd. Comments on Recent Promotional Market Activity

Retrieved on: 
Friday, February 17, 2023
Bank statement, Caveat, GAF Materials Corporation, Indian stock exchange, Standardized Natural Hazards Disclosure Statement, Trinidad and Tobago Securities and Exchange Commission, Security (finance), EDGAR, PARG, Sumathi Best Television Current Reporting Award, OTC Markets Group, Digital twin, Marketing, OTC

All potential investors should solely rely on information provided directly by the Company, which internally manages all investor relations, marketing, and corporate communications.

Key Points: 
  • All potential investors should solely rely on information provided directly by the Company, which internally manages all investor relations, marketing, and corporate communications.
  • Company information that may be relied upon may be found on www.otcmarkets.com , www.sec.gov and www.poweramericas.net .
  • These press releases, Disclosure Statements and Form 8-Ks are displayed on the Company's page on the OTC Markets' website.
  • The Company had no knowledge of the subject promotional materials until notified by the OTC Markets Issuer Compliance Team which monitors and enforces OTC Markets Promotion Policies.

Power Americas Resource Group Seats First Members of Audit Committee

Retrieved on: 
Thursday, February 16, 2023
CFO, Wind Powering America, Audit committee, PARG, Digital twin, OTC, Private law

MIRAMAR, FL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Power Americas Resource Group Ltd. (OTC: PARG) (the “Company” or “PARG”), a publicly traded, fully reporting emerging growth company commercializing its Digital Twin technology “Twin Infra” for the international construction industry, is pleased to announce that the Company has seated three board members for its recently announced Audit Committee.

Key Points: 
  • MIRAMAR, FL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Power Americas Resource Group Ltd. (OTC: PARG) (the “Company” or “PARG”), a publicly traded, fully reporting emerging growth company commercializing its Digital Twin technology “Twin Infra” for the international construction industry, is pleased to announce that the Company has seated three board members for its recently announced Audit Committee.
  • The first three Board Members of its Audit Committee include Prabhu Rajendiran, Kumar Elumalai, and Ramasamy Balasubramanian, Treasurer, CFO & Chairman of Power Americas Resource Group.
  • Additionally, the Company is pleased to announce that it has retained Lockett + Horwitz, a Professional Law Corporation, as its special securities counsel.
  • “We continue to build an external and internal team to help us create, manage, and officiate the unique opportunity we envision for Power Americas in the rapidly expanding Digital Twin marketplace,” stated Ramasamy Balasubramanian, Treasurer, CFO & Chairman.

Power Americas Resource Group Adds Prabhu Rajendiran as an Independent Board Member

Retrieved on: 
Wednesday, February 8, 2023
Companies Act, Wind Powering America, ICAI, Income tax, Risk, Independent Board for Presbyterian Foreign Missions, Education, OTC, Institute of Chartered Accountants of India, Institute of Cost Accountants of India, Service industries, Digital twin, PARG, Associate, ICMAI, Insurance, Hotel

MIRAMAR, FL, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Power Americas Resource Group Ltd. (OTC: PARG) (the “Company” or “PARG”), a publicly traded, fully reporting emerging growth company commercializing its Digital Twin technology “Twin Infra” for the international construction industry, is pleased to announce that it has added Mr. Prabhu Rajendiran as an Independent Board Member.

Key Points: 
  • MIRAMAR, FL, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Power Americas Resource Group Ltd. (OTC: PARG) (the “Company” or “PARG”), a publicly traded, fully reporting emerging growth company commercializing its Digital Twin technology “Twin Infra” for the international construction industry, is pleased to announce that it has added Mr. Prabhu Rajendiran as an Independent Board Member.
  • Mr. Rajendiran has worked extensively with large domestic companies and multinational entities in setting up or rationalizing business models and nationwide distribution structures.
  • “We are most pleased to simultaneously increase our intellectual capital at Power Americas and our transparency,” stated Mark Croskery, Chief Executive Officer, Power Americas Resource Group.
  • “Prabhu Rajendiran has accomplished so much in his career already and we want Power Americas to be a part of his continued ascent.